Critical Contrast: Praxis Precision Medicines (NASDAQ:PRAX) vs. Actinium Pharmaceuticals (NYSE:ATNM)
by Amy Steele · The Cerbat GemActinium Pharmaceuticals (NYSE:ATNM – Get Free Report) and Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.
Risk and Volatility
Actinium Pharmaceuticals has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.79, meaning that its stock price is 179% more volatile than the S&P 500.
Profitability
This table compares Actinium Pharmaceuticals and Praxis Precision Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Actinium Pharmaceuticals | N/A | -100.85% | -47.89% |
| Praxis Precision Medicines | N/A | -34.15% | -32.42% |
Analyst Ratings
This is a summary of recent recommendations and price targets for Actinium Pharmaceuticals and Praxis Precision Medicines, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Actinium Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
| Praxis Precision Medicines | 2 | 0 | 15 | 3 | 2.95 |
Actinium Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 327.35%. Praxis Precision Medicines has a consensus target price of $612.42, suggesting a potential upside of 107.24%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Actinium Pharmaceuticals is more favorable than Praxis Precision Medicines.
Institutional and Insider Ownership
27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Actinium Pharmaceuticals and Praxis Precision Medicines”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Actinium Pharmaceuticals | $35.09 million | 1.05 | -$48.82 million | $0.36 | 3.25 |
| Praxis Precision Medicines | $8.55 million | 964.99 | -$303.27 million | ($12.93) | -22.85 |
Actinium Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Praxis Precision Medicines beats Actinium Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
About Praxis Precision Medicines
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.